相关实验视频

Updated: Jun 23, 2025

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

一种新型合成α-分泌酶的治疗作用

Sung Bin Kim¹, Bo-Ram Mun², Sung Yoon Kim¹

¹School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.

Frontiers in aging neuroscience

|June 24, 2024

概括

合成的α-分泌酶 (SAS) 有效地减少粉样β (Aβ) 斑块,并改善阿尔茨海默病模型中的认知能力. 这种新型蛋白质专门针对Aβ,为大脑疾病提供了一个有前途的治疗策略.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
生物化学生物化学

背景情况:

粉样β (Aβ) 积累是阿尔茨海默病 (AD) 发病的一个关键因素.
消除Aβ是一种潜在的治疗方法.
目前用于Aβ降低的方法面临挑战.

研究的目的:

开发和评估一种新型的融合膜蛋白,合成α-分泌酶 (SAS),用于向的Aβ裂变.
在阿尔茨海默病小鼠模型中评估SAS在降低Aβ和改善认知功能的有效性.

主要方法:

构想并设计了SAS融合蛋白.
经过验证的SAS活性在哺乳动物细胞的α位点分裂粉样蛋白前体蛋白 (APP) 和Aβ.
使用腺相关病毒血清型9 (AAV9) 将SAS输送到小鼠海马体.
使用了5xFAD小鼠,这是阿尔茨海默病的既定模型.

主要成果:

在哺乳动物细胞中,SAS成功地在α位点分离了APP和Aβ.
在5xFAD小鼠的海马中过度表达SAS降低了可溶性Aβ和斑块水平.
在5xFAD小鼠中,SAS的使用显著减轻了认知缺陷,行为测试证实了这一点.
SAS 显示出高基质特异性,使其与其他蛋白酶区别开来.

结论:

SAS是一种有效的酶,用于增强非粉原性APP处理.
在阿尔茨海默病中,SAS显示为减轻Aβ负担的治疗剂.
SAS的严格基质特异性表明,它对潜在的临床应用具有有利的安全性.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.粉样蛋白β清除率粉胺-β降解酶降解酶核包含性 a 核包含性 a 合成的α-分泌酶.

更多相关视频

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...